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models are available, but none of them faithfully recapitulates human pathology and are not suitable
for drug screening. To create a new in vitro tauopathy model, we generated a footprint-free triple
MAPT-mutant human induced pluripotent stem cell line (N279K, P301L, and E10116 mutations) us-
ing clustered regularly interspaced short palindromic repeats-FokI and piggyBac transposase technol-
ogy.Mutant neurons expressed pathogenic 4R and phosphorylated TAU, endogenously triggered TAU
aggregation, and had increased electrophysiological activity. TAU-mutant cells presented deficiencies
in neurite outgrowth, aberrant sequence of differentiation to cortical neurons, and a significant activa-
tion of stress response pathways. RNA sequencing confirmed stress activation, demonstrated a shift
toward GABAergic identity, and an upregulation of neurodegenerative pathways. In summary, we
generated a novel in vitro human induced pluripotent stem cell TAU-mutant model displaying neuro-
degenerative disease phenotypes that could be used for disease modeling and drug screening.
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2431. Introduction
Tauopathies are a group of sporadic and familial neurode-
generative disorders, which are characterized by filamentous
accumulations of hyperphosphorylated TAU proteins in neu-
rons and glial cells [1]. They are classified into primary or
secondary tauopathies depending on whether TAU pathol-
ogy is the major contributing factor to neurodegeneration
or if it is associated with other pathologies. Primary tauopa-
thies include Pick’s disease, progressive supranuclear palsy,
corticobasal degeneration, argyrophilic grain disease, fron-
totemporal dementia with parkinsonism linked to chromo-
some 17 (FTDP-17), globular glial tauopathy, and others.
On the other hand, secondary tauopathies represent a rather
heterogeneous group of disorders of quite diverse etiology,
including Down’s syndrome, Lewy body disorders, and,
the most prevalent and studied one, Alzheimer’s disease
(AD). AD represents the most common cause of dementia
in the elderly, clinically characterized by a progression
from episodic memory problems to a slow global decline
of cognitive function that leaves patients with end-stage
AD bedridden and dependent on custodial care, with death
occurring on average 9 years after diagnosis. Histopatholog-
ically, AD is distinguished by the presence of both plaques of
b-amyloid and neurofibrillary tangles composed of hyper-
phosphorylated TAU species, with both pathological hall-
marks playing a fundamental role in AD pathology [2].
TAU is a microtubule-stabilizing protein encoded by the
microtubule-associated protein TAU (MAPT) gene on chro-
mosome 17q21.31 spanning 16 exons, with exons 2, 3, and
10 being alternatively spliced. Differential splicing results
in the expression of six different isoforms present in the adult
human brain. TAU isoforms differ in the absence or presence
of one or two 29 amino acid inserts (0N, 1N, 2N) in the
amino-terminal part (encoded by exons 2 and 3) and in the
presence of three or four highly conserved repetitive
microtubule-binding domains in the C-terminal part (3R or
4R, encoded by exons 9–12) [3]. In both human and mouse
fetal brain, only the shorter 3R isoforms are detected,
whereas 4R isoforms arise during development, and both
isoforms become equally expressed in the adult brain [1].
The developmental switch of incorporating exon 10 in the
TAU protein results in the addition of microtubule-binding
repeats, which may stabilize microtubules. Accordingly,
expression of 3R isoforms in fetal neurons may support their
higher plasticity, required for process formation and neurite
elongation, during neuronal development. Aberrant regula-
tion of exon 10 splicing in the adult brain has been identified
as a major cause of tauopathies, resulting in an imbalance of
3R and 4R TAU isoforms [4].
More than 50 mutations in the MAPT gene have been
described so far [5]. MAPT mutations are typically associ-
ated with FTDP-17 but have also been observed for Pick’s
disease, progressive supranuclear palsy, corticobasal degen-
eration, and globular glial tauopathies. Phenotypes caused
by MAPT mutations are heterogeneous, even within familyFLA 5.5.0 DTD  JALZ2627_proofrelatives carrying the same mutation(s) [6]. Most mutations
are located in exons 9–12 encoding for the repeat regions and
adjacent introns and affect either protein levels or the alter-
native splicing of the pre-mRNA [6]. Several of these muta-
tions cause a decrease in the affinity of TAU for microtubules
and a reduced ability to promote microtubule assembly.
Other mutations affect exon 10 splicing capacity, resulting
in a shift in the physiological ratio between 3R and 4R iso-
forms [7]. In addition, some mutations facilitate TAU phos-
phorylation, the main and most diverse post-translational
modification of TAU, causing a significant heterogeneity
of different TAUmolecules. Increased TAU phosphorylation
is associated with its aggregation into neurofibrillary tangles
in AD and other tauopathies, likely affecting synaptic activ-
ity, neuronal physiology, and underlying neurodegeneration
[8].
In an attempt to reproduce the pathology present in AD
and other tauopathies, numerous animal models have been
generated based on the (over)expression of wild-type
(WT) or mutant forms of human TAU. Depending on the
TAU variant over-expressed and the genetic background of
the animal, TAU aggregation and phosphorylation, neuronal
and synaptic activity impairments, behavioral deficits, and
motor disturbances have been described [9]. With the advent
of induced pluripotent stem cell (iPSC) technology, iPSCs
have been generated from individuals carrying different
MAPT mutations and differentiated into neurons. Although
different aspects of tauopathy have been reported, findings
are heterogeneous, possibly due to the presence of different
MAPTmutations, in methods used and/or the phenotypic as-
pects that were evaluated [10–13].
To generate a robust model for tauopathies also suitable
for drug discovery screenings, we generated a footprint-
free triple MAPT-mutant human iPSC line that when
differentiated to cortical neurons reproduces several neuro-
degenerative aspects, including modified TAU isoform
expression, TAU aggregation, altered electrophysiological
activity, aberrant cortical neuron differentiation, and an acti-
vation of pathways related to inflammation, oxidative stress,
endoplasmic reticulum/unfolded protein response (ER/
UPR), and apoptosis. RNAseq analysis of WT and MAPT-
mutant cells confirmed these findings and further revealed
a shift of differentiation into GABAergic neurons in the
mutant cells, as well as an increased expression of pathways
previously linked to neurodegeneration.2. Results
2.1. Selection ofMAPTmutations and generation of triple
TAU-mutant iPSC lines
To generate a robust model reproducing different charac-
teristics of tauopathies, we introduced three mutations
(N279K, P301L, and E10116) in and next to exon 10 of
theMAPT gene in WT donor healthy-derived human iPSCs.
The N279K and P301L mutations are among the most 19 July 2018  8:16 pm  ce
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360prevalent FTDP-17–linked mutations, causing early onset
and aggressive disease progression. These mutations are
characterized by the presence of phosphorylated TAU spe-
cies in both neurons and glia and an elevated prevalence of
4R TAU isoforms [14]. The E10116 mutation is located in
the intron between exons 10 and 11, resulting in an alteration
of a stem-loop structure affecting splicing of the pre-mRNA,
and increasing incorporation of exon 10 in TAU, thus
increasing the expression of 4R TAU isoforms [15].
Together, these three mutations account for up to 60% of
all FTDP-17 cases [16].
We used clustered regularly interspaced short palin-
dromic repeats (CRISPR)-FokI nucleases to introduce the
mutations, as they are known to cause less off-target effects
than the CRISPR-Cas9 system [17]. The donor plasmid
used for homology-directed recombination (gently pro-
vided by Dr. Kosuke Yusa, Wellcome Trust Sanger Insti-
tute, UK [18]) included a positive (hygromycin resistance
[HYGR]) and a negative (thymidine kinase [TK]) selection
cassette, with a 30 homology arm containing the three
selected point mutations (Fig. 1A). After HYG selection
and clonal expansion, the recombinant clones were evalu-
ated for in situ integration (Fig. 1B and C) and presence
of the three selected mutations. To excise the HYG/TK se-
lection cassette without any additional modification in the
genome, the piggyBac transposase system was used, by us-
ing piggyBac inverted terminal repeats flanking the HYG/
TK cassette. An endogenous TTAA site was present next to
the N279K mutation, allowing the employment of this
strategy (Fig. 1A) [18]. Following transient expression of
the piggyBac transposase, cells were cultured with 1-(2-
deoxy-2-fluoro-1-D-arabinofuranosyl)-5-iodouracil (FIAU)
to select for cells from which the TK-containing selection
cassette was removed [18] (see Fig. 1 for a scheme about
the generation of the mutant cells). This resulted in the
generation of heterozygous triple MAPT-mutant hiPSCs
displaying a pluripotent phenotype (Fig. 1G), which re-
tained their capacity to differentiate into the three germinal
layers on embryoid body formation (Fig. 1H). The array
comparative genome hybridization analysis confirmed
that genome integrity was preserved after CRISPR-FokI
treatment (Supplementary Fig. 1).361
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3772.2. Neuronal differentiation and TAU expression
To evaluate the effect of MAPT mutations, we differenti-
ated both WT and mutant (triple TAU-mutant) iPSCs to
cortical neurons for up to 200 days, using a protocol devel-
oped by Shi et al. [19]. We first evaluated the expression
of MAPT isoforms by qRT-PCR based on the presence/
absence of exon 10 (3R- vs. 4R-MAPT isoforms) during dif-
ferentiation. We observed a significant alteration of the 3R/
4R ratio in triple TAU-mutant neurons, as 4R-MAPT mRNA
was already highly expressed in mutant cells on day in vitro
(DIV) 32 (neural progenitor stage, neural precursor [NPC]).
Four repeat-MAPT RNA could only be detected fromFLA 5.5.0 DTD  JALZ2627_proofDIV160 onward in WT neurons (Fig. 2A–F), consistent
with the notion that 4R-TAU expression is only found in
mature neurons. The expression of 4R TAU protein was
also confirmed by Western blotting (Fig. 2G).
On DIV65 and DIV94, we assessed the protein levels of
total TAU and phosphorylated TAU isoforms by Western
blotting. As shown in Fig. 2H–J, more total and phosphory-
lated TAU isoforms (determined by the use of the AT270 and
AT8 antibodies) protein was present at both time points. We
also assessed the presence of detergent-insoluble TAU iso-
forms, finding little if any presence of insoluble TAU iso-
forms within the mutant neurons (data not shown).
As expression of aberrant TAU isoforms has been re-
ported to cause TAU disassembly and accumulation in
neuronal soma [14], we assessed TAU distribution within
neuronal cells by visualization of total TAU by confocal mi-
croscopy. As can be clearly observed (Fig. 2K), differential
pattern of TAU distribution was seen between WT and
mutant neurons. In WT cells, TAU was homogeneously
distributed along neuronal prolongations, whereas in mutant
neurons, TAU was clearly more concentrated within the cell
soma, consistent with an abnormal physiology in the main-
tenance and/or functioning of TAU in the mutant neurons.2.3. TAU aggregation
We next explored the aggregation potential of TAU in the
triple mutant-TAU neurons by amplified luminescent prox-
imity homogeneous assay (alpha-LISA technology). The
assay uses antibodies recognizing human TAU (hTAU10)
and labeled with either a donor or acceptor bead. When
TAU proteins are aggregated, the proximity of the donor-
and acceptor-labeled antibodies leads to the emission of
light at 615 nm. The assay hence allows the quantitative
detection of aggregated TAU (hTAU10/hTAU10 signal) in
a high-throughput-compatible setting [20].
As we previously reported [20], in WT neurons, no TAU
aggregation can be observed unless the cells are transduced
with an adeno-associated viral vector encoding P301L
mutant TAU and are simultaneously seeded with K18 (ag-
gregates of recombinant 4R TAU produced in vitro). K18
triggers aggregation of overexpressed but not endogenously
produced TAU in control cells, which was used as a positive
control in our assays. Similarly, WT cells did not show an in-
crease in hTAU10/hTAU10 signal when only seeded or
transduced. In contrast, we observed a twofold increase in
hTAU10/hTAU10 signal in triple TAU-mutant neurons
following either P301L transduction or K18 seeding sepa-
rately (Fig. 2L and M). Interestingly, we quantified a 15-
fold increase in hTAU10/hTAU10 signal when P301L was
overexpressed in TAU-mutant neurons on DIV60, increasing
up to 50-fold 10 days later (DIV70, Fig. 2L). We also eval-
uated if aggregated TAU was also phosphorylated in mutant
neurons by quantifying AT8 detection using AlphaLISA.
The signal for AT81/phosphorylated TAU in untreated or
seeded cells with K18 was significantly higher in mutant 19 July 2018  8:16 pm  ce
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Fig. 1. Design and generation of the triple TAU-mutant hiPSC lines. (A) General overview of the experimental design and strategy used to generate the template
DNA including the double selection cassette and the introduction of the selected mutations into the genome through direct genome targeting mediated by
tailored CRISPR-FokI nucleases and homologous recombination (HR) between highly similar sequences. (B) Layout of the nucleofection (NF) with
CRISPR-FokI nucleases plus template DNA and HYG selection to generate iPSC clones harboring the GFP1 selection cassette. (C) Example of junction assay
(JA) PCRs to discriminate the presence or absence of the selection cassette in the MAPT gene in different clones. (D) Experimental design for excision of se-
lection cassette byNF of the piggyBac Transposase followed by FIAU negative selection. (E) JA PCRs demonstrating correct integration of the selection cassette
before and after the excision of the piggyBac Transposase; and random integration (RI) PCRs demonstrating absence of random cassette integration in the
genome. (F) Sequencing of theMAPT gene following genetic modification demonstrating presence of the three mutations in heterozygosity. (G)MAPT-mutant
hiPSCs express typical pluripotency markers as SOX2, SEEA4, NANOG, TRA1-81, OCT4, and TRA1-60. Hoechst 33258 (blue) was used as nuclear marker.
Scale bars: 50 mm. (H) Results of embryoid body formation and characterization using the score card assay (three germ layer differentiation and loss of plu-
ripotency marker gene expression). Abbreviations: bef., before; Tem., template; lad., ladder Q13.
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584neurons (Fig. 2N), suggesting that TAU aggregates detected
are also hyperphosphorylated, similar to the neurofibrillary
tangles found in AD affected brains [3]. Overall, these
studies indicate that endogenously expressed triple mutant-
TAU may be sufficient to seed for TAU aggregation in vitro.585
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6382.4. Triple TAU-mutant neuronal progeny displays
increased electrophysiological activity
Patient iPSC-derived neurons with MAPT mutations
affecting exon 10 splicing have been previously described to
display a faster maturation phenotype as defined by their elec-
trophysiological properties [21]. We hypothesized that this
phenotype would also be reproduced in the triple mutant-
TAU iPSC progeny. We applied whole-cell patch-clamp on
iPSC-derived neurons to record action potentials and voltage-
gated currents on an early (DIV70) and a late (.DIV90) stage
during neuronal differentiation. At both time points, WT and
TAU-mutant cells displayed a comparable percentage of cells
firing spontaneous (Fig. 3D and F) and evoked (Fig. 3E and
G) action potentials. Quantification of the number of sponta-
neous (Fig. 3H and J) and evoked (Fig. 3I and K) action poten-
tials revealed a similar firing frequency between WT and
TAU-mutant cells on DIV70 and on .DIV90. TAU-mutant
neurons displayed slightly decreased inward and outward
voltage-gated current densities compared with WT neurons
on DIV70 (P , .05; Fig. 3L and M), whereas no differences
were observed at.DIV90 (Fig. 3N and O).
Basic electrophysiological membrane properties (capaci-
tance and potential) were similar in WT and TAU-mutant
cells on DIV70 and.DIV90, except that the membrane po-
tential on .DIV90 was more depolarized in TAU-mutant
than that in WT cells (WT: 255 6 2 mV, mutants: 248 6
2 mV; P 5 .0172).
To exclude the intrinsic bias associated with single-cell
patch-clamping, wherein only a limited number of individ-
ual cells are evaluated and without considering the overall
neuronal network activity, we assessed electrophysiological
properties of the neurons using multielectrode arrays
(MEAs). Co-culture of iPSC-derived neurons with murine
primary astrocytes (1:1 ratio) was used, as this hastens elec-
trophysiological maturation of iPSC neurons [22]. MEAs
provide information on the electrical properties of the whole
neuronal population by measuring extracellular potentials
across electrodes distributed throughout the culture wells.
Using this experimental setup, we observed a significant in-
crease in the number of spikes, bursts, and burst frequency in
triple TAU-mutant neurons compared with WTs (on DIV60,
Fig. 3P–S), suggesting an increase in the electric activity due
to the TAU mutations.639
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6452.5. Aberrant differentiation of TAU-mutant iPSCs to
cortical neurons
We next assessed if presence of the three MAPT muta-
tions affected the differentiation of iPSC toward corticalFLA 5.5.0 DTD  JALZ2627_proofneurons. We analyzed neurons at different time points for
expression of cortical layer markers both at the mRNA and
protein levels (Fig. 4). As shown in Fig. 4A–L, early during
differentiation (DIV32–45), mutant cells displayed
increased levels of early neuronal and deeper cortical layer
markers, including FOXG1, CTIP2, and BRN2 compared
with WT cells, suggesting an accelerated maturation of
mutant cells. By contrast, mutant cells expressed lower
levels of transcripts and/or proteins of markers for superfi-
cial layer cortical neurons, such as SATB2, while these
levels progressively increased from DIV65 onward during
the differentiation ofWT cells. A similar trend was observed
for TBR1 (Fig. 4C), which in addition to be a marker for
deep cortical layers, also plays a role in glutamatergic pro-
jection and, therefore, in the development of cortical layers
[23]. Differences in cell proliferation (EdU1 cells) were
observed as well betweenWTandmutant cells, with a higher
prevalence of EdU1 WT neurons at early time points
(DIV40) but a greater number of EdU1TAU-mutant neurons
later (DIV68, Fig. 4M).
To further address the impact of the triple MAPT muta-
tions on the neuronal progeny, we performed RNAseq anal-
ysis on WTand mutant iPSC neuronal progeny harvested on
DIV70 and DIV110. Unsupervised principal component
analysis demonstrated that WT and triple TAU-mutant neu-
rons, at both time points, clustered separately (Fig. 5A).
1490 (DIV70) and 1868 (DIV110) genes were differentially
expressed between both genotypes (adjusted P-value , .05
& log twofold change), 395 of which were shared for both
time points (Fig. 5B). We next analyzed the different cell
populations using a set of markers that define different
neuronal populations, developmental stages, and different
forebrain areas [24]. This demonstrated that, as expected,
DIV70 and DIV110 progeny clustered together, with a clear
distinction between WT and mutant progeny at both time
points (Fig. 5C). Further analysis also demonstrated that
expression of typical glutamatergic and GABAergic marker
genes was significantly different. Mutant cells expressed
lower levels of glutamatergic markers and increased levels
of GABAergic markers compared withWT cells, differences
that were more pronounced on DIV110 (Fig. 5D). This was
further substantiated by ingenuity pathway analysis, demon-
strating significantly lower expression of glutamatergic
signaling pathway as well as genes involved in synaptic
long-term potentiation (LTP) in TAU-mutant neurons
(Fig. 5E and F).
As differences in the balance between excitatory and
inhibitory transcripts were observed at the transcriptome
level betweenWTand triple TAU-mutant cells, we immuno-
stained DIV88 progeny with antibodies against the gluta-
mate (excitatory) and GABA and glycine (inhibitory)
neurotransmitter transporters, vGlut1 and vGat, respectively.
Quantification was performed based on the intensity thresh-
olds and normalized to the number of DAPI1 nuclei or
the expression of the neuronal marker b-3-tubulin
(Supplementary Fig. 2A–F). The area and integrated density 19 July 2018  8:16 pm  ce
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Fig. 2. Increased Q144RTAU expression and TAU aggregation in the triple-mutant TAU cortical neurons. (A–F) qRT-PCR analysis showing expression of 3R and
4R TAU isoforms during the neuronal differentiation of both WT and triple TAU-mutant cells. (A) Relative expression to glyceraldehyde 3-phosphate
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874(product of the area by the intensity) of vGat-positive stain-
ing related to the number of nuclei was higher in TAU-
mutant cells than in WT cells (even if this did not reach
statistical significance, Supplementary Fig. 2B and C).
Nevertheless, when we compared the area of vGat-positive
staining to the total area of b-3-tubulin, these differences
were not obvious, with presence of 640% of positive area
for both vGlut and vGat markers referred to the b-3-
tubulin positive area. This suggests that it may be necessary
to analyze many more markers for excitatory vs. inhibitory
neurons and that single marker analysis might not reveal
the differences present between WT and mutant cultures.
We also evaluated the presence of GFAP1 cells in the
cultures (Supplementary Fig. 2E–G). On DIV65,
12.01 6 1.82% of the cells present in the culture expressed
the GFAP antigen, consistent with previous reports [19].
Subtle differences were found in the percentage of GFAP1
cells between WT and mutant cells (WT: 9.05 6 2.29%
vs. mutant: 14.97 6 1.61% of GFAP1 cells), but this did
not reach statistical significance. Notably, most of these
GFAP1 cells (82.19 6 5.23% in total) presented a bipolar
elongated phenotype, which would resemble radial-glial–
like cells, present in the developing brain [25].875
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8952.6. Mutant cells display a stress gene signature
Several reports indicated the presence of mitochondrial
and ER/UPR stress in MAPT mutant iPSC-derived neurons
and in neurons from tauopathy mouse models and patients
[26]. As we observed a progressive cell loss in mutant
neuronal cultures compared with WT, we evaluated the
RNAseq data to determine if different stress pathways
were more highly expressed in triple TAU-mutant progeny
compared with WT cells. Gene ontology pathway analysis
revealed increased expression of gene ontology terms asso-
ciated with cellular stress as, for example, “response to inter-
feron-g”, “positive regulation of reactive oxygen species
metabolic process”, “regulation of extrinsic apoptotic
signaling pathway”, “activation of signaling protein activity
involved in unfolded protein response,” and “positive regula-dehydrogenase (GAPDH) of 4RMAPT isoforms during the differentiation ofWT (b
expression ratio during differentiation of both cell types. (C) 4R MAPT isoform e
neurons. (D) 4R/3RMAPT isoform ratio expression levels during differentiation of
levels during differentiation of TAUmutant cells relative toWT neurons. (F) TotalM
WT neurons. Data are represented as mean 6 standard error of mean (SEM) of
analysis for total TAU expression inWTand triple TAUmutant neurons following i
of 4R TAU expression only in mutant cells (arrow). (H–J) Western blot analysis o
tibodies) of protein extracts from WT and mutant neuronal progeny on DIV 65 (H
sented as mean6 SEM of N5 3 independent experiments. (K) Immunocytochem
and mutant neurons on DIV65. Hoechst 33258 (blue) was used as nuclear mark
measured in both WT and triple TAU-mutant neuronal progeny in nontreated neu
cultivated in the presence of the K18 seed and transduced to overexpress the P301L
control. (I) hTAU10/hTAU10 alphaLISA values measured in both WT and triple T
DIV60 and DIV70, and alphaLISA levels measured on DIV70 in both cell types tra
values referred to phosphorylated TAU aggregation from WT and mutant cells see
licates, One-way analysis of variance. *P , .05, **P , .01, ****P , .0001 (Dunn
relative fluorescence units; A.U., arbitrary units.
FLA 5.5.0 DTD  JALZ2627_prooftion of NFkB signaling”, in triple TAU-mutant cells
compared with WT progeny at both time points analyzed
(DIV70 and 110, Supplementary Tables 1 and 2). Ingenuity
pathway analysis performed on selected pathways also
demonstrated increased expression of the genes involved
in these pathways in mutant cells, as exemplified by the
NFkB signaling pathway, represented in Fig. 6Q.
The increased activation of stress pathway genes within
the TAU-mutant neurons was confirmed by qRT-PCR for
marker genes of the oxidative stress, ER/UPR stress, and in-
flammatory response pathways, on different time-points
throughout neuronal differentiation (Fig. 6A–M). This was
confirmed at the protein level because the expression of
the tumor necrosis factor receptor 1 (implicated in inflam-
matory response) and CHOP (involved in ER/UPR) was
significantly upregulated within the mutant neurons
(Fig. 6N–P).
In addition, to substantiate the observation that triple
TAU-mutant progeny were progressively lost from culture
over time, we assessed the frequency of apoptotic cells in
culture. We observed significantly more CASPASE31 neu-
rons in the triple TAU-mutant iPSC progeny compared
with WT (Fig. 6R and S). Moreover, apoptotic nuclei (char-
acterized by a reduction of nuclear size and compaction of
genomic material) were also frequently observed at the
beginning of neuronal maturation (wDIV40), but this only
in triple TAU-mutant progeny (Fig. 6T and U). Thus, triple
TAU-mutant neuronal progeny, at least under these culture
conditions, suffered from oxidative, protein folding, and in-
flammatory stress, which might underlie the increase for
apoptosis.2.7. Neurite outgrowth
TAU is a microtubule-stabilizing protein implicated in
neurite formation, stabilization, and maintenance, as part of
its cytoskeletal plasticity functions [26]. Because the MAPT
mutations altered the ratio between 3R- and 4R-TAU iso-
forms (Fig. 2), we hypothesized that differences in neurite
formation and outgrowth might be present between WT andlack) and triple TAU-mutant (Mut, gray) neurons. (B) 4R/3RMAPT isoform
xpression levels during differentiation of TAU-mutant cells relative to WT
TAUmutant cells relative to WT neurons. (E) 3RMAPT isoform expression
APTexpression levels during differentiation of TAUmutant cells relative to
N 5 3–4 independent experiments. *P , .05, **P , .01. (G) Western blot
ncubation with or without l-phosphatase (1/2), demonstrating the presence
f total TAU (HT7 antibody) and phosphorylated forms (AT270 and AT8 an-
) and DIV 94 (I), quantified based on intensity signal in (J). Data are repre-
istry showing cellular localization of TAU expression (HT7 antibody) in WT
er. Scale bar: 50 mm. (L) hTAU10/hTAU10 alphaLISA values on DIV60
rons, in neurons cultivated in the presence of the K18 seed and in neurons
mutant TAU. Cells that were seeded and transduced were used as a positive
AU-mutant transduced neurons without the presence of the K18 seeding on
nsduced and in the presence of the K18 seeds. (N) AT8/hTAU10 alphaLISA
ded in the absence or presence of the K18 seed. N 5 3–6 independent rep-
ett’s multiple comparison test vs. nonseeded control). Abbreviations: RFU,
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Fig. 3. Altered electrophysiological activity of TAU-mutant iPSC-derived cortical neurons. (A) Representative recording (WT neuron on DIV70) of sponta-
neous action potentials. No current injection was applied. (B) Experimental current pulse step protocol (top panel) and representative traces (triple TAU-
mutant neuron at .DIV90) of membrane potential responses to current injections (lower panel). The membrane potential was clamped at approximately
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Progeny from WT and TAU-mutant iPSCs on DIV40 were
plated and allowed to extend neurites for 3 days before fixa-
tion.We used high-content imaging to assess cell morphology
and neurite frequency and length following stainingwith anti-
TUJI antibodies.
Compared with WT iPSC progeny, significantly fewer
TAU-mutant neurons displayed a multi-branching pheno-
type, with most of TAU-mutant cells having a bi-polar
morphology (Supplementary Fig. 3H and I). We found an
almost 50% reduction in the number of branching points
in the mutant compared with WT cells (Supplementary
Fig. 3B). We also found a reduction in the total area covered
by neurites, the total neurite length, and the length of all neu-
rites per cell (Supplementary Fig. 3C–E) in mutant
compared with WT cells, even if the cell density was the
same in both cultures (Supplementary Fig. 3G). On the other
hand, the length of each neurite branch was slightly
increased in mutant cells (Supplementary Fig. 3F).1138
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11652.8. Confirmation of phenotypic features in a second
independent triple TAU-mutant cell line
We evaluated if the findings obtained for the triple
mutant-TAU neurons could be reproduced using a second
and independently generated genome-engineered line. This
independent mutant line reproduced the features displayed
by the first mutant line, including increased expression of
4R-TAU isoforms already on DIV32 (altering therefore the
3R/4R ratio; Supplementary Fig. 4). Action potential pro-
portions and frequencies obtained from the second indepen-
dent mutant line on DIV70 were also similar to the action
potential properties of the first mutant line (Supplementary
Fig. 5A–F). The second independently generated triple
TAU-mutant line also showed altered cortical marker
expression (by qRT-PCR and immunostaining) similar to
the data from the first line (Supplementary Figs. 6 and 7);
a significant increased expression of genes within the oxida-
tive stress, ER/UPR and inflammatory pathways and a
higher prevalence of apoptotic cells (Supplementary
Fig. 7); and aberrant neurite outgrowth (Supplementary
Fig. 8).265 mV between current pulses. The maximal amount of action potentials (red trac
Experimental voltage pulse step protocol (top panel) and representative traces (W
and outward currents. The amplitude of the peak inward current (red trace in gra
quantified at 130 mV during the time course indicated by the red dashed box. T
F) and evoked (E and G) action potentials is similar, on DIV70 (WT: n 5 30; mut
frequency of spontaneous (H and J) and evoked (I and K) action potentials is comp
mutant: n 5 8; evoked, WT: n 5 10, mutant: n 5 7) as well as on DIV90 (spontan
Inward and outward current densities are different between WT (n5 24) and TAU
similar on DIV90 (N and O; inward, WT: n5 20, Mut: n5 22; outward, WT: n5
were sampled from four neuronal differentiations. Data are represented as median
Whitney test. *P , .05. (P–S) Electrophysiological activity measured by multi-el
astrocytes from DIV40. (P) Depicts the number of spikes (note that astrocytes cul
(.5 spikes per second) and burst frequency detected. (S) Depicts synchronicity.
**P , .01.
FLA 5.5.0 DTD  JALZ2627_proofThese results confirm that the phenotypic changes identi-
fied in the mutant cells are specific for the MAPT mutations
introduced and are not restricted to cell clone-specific ef-
fects.3. Discussion
Tauopathies are a heterogeneous group of diseases char-
acterized by hyperphosphorylation and accumulation of
TAU protein in the brain. Some of these diseases are directly
linked to specific MAPT gene mutations that alter the phys-
iological ratio between 3R- and 4R-TAU isoforms and/or
renders TAU protein more susceptible to aggregation.
Nevertheless, the mechanisms underlying TAU-mediated
neurodegeneration are only partially understood [27].
Although mouse models have been generated (over)ex-
pressing different human TAU variants, these only partially
reproduce human TAU pathology with significant variability
between models depending on the TAU variant expressed
and/or promoter used [9]. In addition, murine neurons
appear to be less sensitive to neurodegeneration compared
with human neurons [28].
The advent of human iPSCs has created the possibility to
study mutations in human cell models. A number of studies
have generated iPSC-derived cells from individuals carrying
different MAPT mutations. These in vitro models reproduce
some aspects of tauopathies, including the presence of
altered TAU isoforms expression, TAU hyperphosphoryla-
tion, activation of ER/UPR stress pathways, accelerated
electrophysiological maturation, and/or impaired neurite
outgrowth [10–13,21]. However, depending on the lines
studied, some but not all of these phenotypes were
described simultaneously.
Ideally, drug discovery and validation platforms should
use cell models wherein most of these TAU-associated phe-
notypes are present and can be compared with WT control
lines, to prove the causal relation of the phenotype. We
therefore created an iPSC-derived model that reproduces
most of the phenotypes described elsewhere by introducing
the three mutations found in .60% FTDP-17 patients
(N279K, P301L, and E10116) [16] in a single iPSC line.
We introduced the three mutations in a footprint-free
manner in hiPSCs, combining the CRISPR-FokIe) in response to a depolarizing current pulse was counted for every cell. (C)
T neuron on DIV70) of current responses showing voltage-activated inward
y dashed box) was determined for every cell. Outward peak currents were
he percentage of WT and TAU-mutant neurons firing spontaneous (D and
ant: n 5 23) as well as on .90 DIV (WT: n 5 26; Mutant: n 5 35). Firing
Q16arable in WTand TAU-mutant neurons, on DIV70 (spontaneous, WT: n5 7;
eous, WT: n 5 22, mutant: n 5 16; evoked, WT: n 5 21, mutant: n 5 22).
-mutant (n5 14) neurons on DIV70 (P, .05; L and M), whereas they were
19; Mut: n5 22). The number of patched cells is represented by n; all cells
with interquartile range. Statistical analysis was performed using a Mann-
ectrode arrays (MEAs) on DIV65 neural progeny co-cultured with primary
tured alone do not display any activity). Q and R show the number of bursts
N 5 3 independent replicates. All data are means 6 SD, t test. *P , .05,
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Fig. 4. Altered cortical neuron differentiation from TAU-mutant iPSCs. (A–G) qRT-PCR analysis for deep and superficial cortical layer neuron marker gene
expression during differentiation of WT (black) and TAU-mutant iPSC (gray) progeny (B3TUB, FOXG1, TBR1, CTIP2, BRN2, CUX1, and SATB2). Gene
expression levels are shown as fold changes relative toWTNPCs fromDIV32 (gene expression was normalized to the housekeeping geneGAPDH). (H) Graph-
ical representation of different cortical layer marker genes. (I–L) Representative pictures for immunostaining of TUJ1 together with FOXG1, TBR1, CITP2, and
SATB2 in WT (upper row) and TAU-mutant progeny at the specified time points (middle row). Quantification levels of each marker during differentiation for
both cell types (WT in black and TAU-mutants in gray) depicted in the lower row. (M) DIV40 and DIV68 differentiating cells were incubated with EdU for
3 hours, 24 hours before fixation, followed by staining with an antibody against EdU and TUJ1. A representative picture of both WTand TAU-mutant neuronal
progeny onDIV40 is shown, with quantification of the percentages of EdU1 cells at both time points ofWT (black) and TAU-mutant cells (gray). Hoechst 33258
(blue) was used as nuclear marker. Scale bar: 50 mm. Data are represented as mean 6 SEM of N 5 3–4 independent experiments. *P , .05, **P , .01.
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Fig. 5. Genome-wide transcriptome studies demonstrate significant differences between triple TAU-mutant and WT neurons. RNA sequencing (seq) was per-
formed on WT and TAU-mutant iPSC progeny on DIV70 and DIV110. (A) Principal component analysis (PCA) of WT and TAU-mutant iPSC progeny on
DIV70 and DIV110. (B) Volcano plots at DIV70 (left) and DIV110 (right) illustrating the number of differentially expressed genes (adjusted P-value , .05
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1575nuclease–mediated homology-directed recombination with
the piggyBac transposase–mediated excision of a select-
able cassette, introduced during the homology–directed
recombination [18]. Because of the use of two guide
RNAs, this approach has been shown to cause less off-
target cuts compared with the CRISPR-Cas9 system [17].
We describe that knock-in of the three mutations in the
MAPT gene resulted in an altered 3R/4R-TAU isoform
expression, with high levels of 4R-TAU already found as
early as DIV32 in iPSC neural progeny. The precise
knock-in strategy used, together with the observation of
similar phenotypes in two independently generated lines,
demonstrates conclusively that the MAPT-mutations are
responsible for this observation.
The three introduced mutations have been reported (indi-
vidually) to lead to the incorporation of the exon 10 in the
mRNA (leading to the expression of 4R-TAU isoforms)
and/or expression of pathogenic TAU. Because single or
combinations of dual mutation insertions have not been per-
formed, we cannot firmly state which of the mutations is
responsible for the phenotypes observed. Nonetheless, due
to the wide range of phenotypes, we describe encompassing
most of the phenotypes observed by other studies using sin-
gle TAU-mutated neurons [10–13,21], we hypothesize that
the phenotypes we obtained are the consequence of both
the incorporation of 4R-TAU isoforms and the synergistic
association of the different mutations introduced.
Expression of TAU protein isoforms is brain region and
developmental stage-specific [29]. During fetal develop-
ment, only 3R-TAU isoforms are present, which is believed
to be important to allow dynamic changes in neurites and
synapses formation. Continued presence of 3R-TAU in post-
natal neurons is likely required for the establishment of new
synapses [29]. By contrast, 4R-TAU, which binds microtu-
bules with higher affinity than 3R-TAU, become expressed
in postnatal cortex [29]. The altered ratio between the two
groups of TAU isoforms in the triple mutant neurons may
be responsible for the aberrant neurite outgrowth we
observed. As the assay can be done using a (semi)-automatic
imaging platform, this phenotype would be amenable to
(semi)high-throughput screening to test compounds that cor-
rect mutant TAU–mediated neurite outgrowth abnormalities.
This model might help to understand the role of TAU in neu-
rite outgrowth, branching, or synapse formation and be
potentially useful to test compounds aiming to correct the
observed phenotype.
TAU aggregation is the pathological hallmark that best
correlates with the progression of AD. Although it is
accepted that TAU aggregates are rather a cause than aand log2 fold change.1) between WTand TAU-mutant neurons at DIV70 (1490 g
both stages. (C) Supervised clustering analysis of a selected list of cortical neurona
(D) Supervised clustering analysis for glutamatergic vs. GABAergic marker expre
genuity pathway analysis (IPA) of the glutamate receptor signaling pathway betw
green: highly expressed genes on TAU-mutant neurons). (F) IPA analysis of th
iPSC progeny on DIV 110 (red: highly expressed genes on WT cells; green: high
FLA 5.5.0 DTD  JALZ2627_proofconsequence of neurodegeneration, the precise molecular
mechanisms by which TAU pathology is triggered and pro-
gresses throughout brain areas are not yet well understood. It
is hypothesized that interfering with TAU expression, aggre-
gation, and/or clearance may be a potential strategy for treat-
ing AD and other tauopathies [30], highlighting the need for
in vitro TAU aggregation assays. Both in animal models and
in vitro assays, physiological levels of TAU expression do
not lead to TAU aggregation and requires not only the addi-
tion of recombinant TAU (seeds) but also the expression of
nonphysiological levels of TAU expression (e.g., by overex-
pression of P301LTAU) [20]. In the triple TAU-mutant iPSC
neurons on DIV70, we observed TAU aggregation only by
seeding with K18 fibrils and without TAU overexpression.
Similarly, we also observed a fivefold increase in aggrega-
tion by simply overexpressing TAU and in the absence of
k18 fibrils. Importantly, we observe that TAU aggregates de-
tected in mutant neurons are hyperphosphorylated, in anal-
ogy with which occurs in the brain of patients with AD
[3]. Taken together, our findings suggest that the triple
MAPT mutation is sufficient to seed for TAU aggregation,
with a signal that is directly proportional to the amount of
monomeric TAU availablewithin the cell. As the seeding po-
tential of endogenously expressed TAU has never been
observed in any other in vitro assay, we suggest that triple
TAU-mutant neurons may be a more clinically relevant
model to screen for drugs interfering with TAU aggregation
and/or propagation.
We found, based on RNAseq, qRT-PCR, Western blots,
and functional studies, that triple TAU-mutant neuronal
progeny displayed considerably increased levels of oxida-
tive stress, ER/UPR stress, and activation of inflammatory-
related response marker genes, which were also associated
with an increased number of apoptotic cells. TAU abnormal-
ities have been reported to lead to mitochondrial dysfunction
and increased oxidative stress [31]. In addition, genetic and
biochemical studies have shown that the UPR is activated at
early stages in tauopathy brains [32]. Thus, the tripleMAPT-
mutant iPSC neuronal progeny recreate the TAU-mediated
activation of the oxidative stress, ER/UPR, and inflamma-
tory pathways; possibly also representing targetable pheno-
types.
Transcriptome analysis demonstrated significant de-
creases in the levels of genes involved in the glutamate
signaling pathway and a shift toward the expression of genes
involved in GABAergic signaling in the triple mutant-TAU
cells. Dysfunction of TAU is believed to cause an impaired
microtubule organization that affects synapse organization,
which underlies neurotoxicity and neurodegeneration. Inenes) and DIV110 (1868 genes, green), 395 of which (red) were common at
l markers in normal and TAU-mutant iPSC progeny on DIV70 and DIV110.
ssion in WT and TAU-mutant iPSC progeny on DIV70 and DIV110. (E) In-
een both cell types on DIV110 (red: highly expressed genes on WT cells;
e synaptic long-term potentiation (LTP) pathway in WT and TAU-mutant
ly expressed genes on mutant neurons).
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1717addition to this mechanism, accumulation of TAU within
intact dendritic spines results in synaptic abnormalities,
where it disrupts synaptic function by impairing glutamate
receptor trafficking or synaptic anchoring [33]. Consistent
with this notion, we also observed a downregulation of
markers of LTP pathway in the mutant cells. LTP is a form
of synaptic plasticity believed to be involved in memory for-
mation required for learning and memory [34]. LTP deficits
have been described mostly for amyloidogenic rather than
TAU-mutant models of AD [35]. However, our results
suggest that this phenomenon might also be linked to
TAU-mediated pathogenesis and suggest that the triple
MAPT-mutant model might be a good platform to interrogate
TAU-based disease mechanisms.
Different studies have reported an abnormally enhanced
electrophysiological activity in TAU-mutant animal models
[36,37] and in tauopathy patient-derived neurons [21]. The
mechanisms by which aberrant TAU causes neuronal hyper-
excitability are not yet elucidated, but it is believed that this
may contribute to neuronal dysfunction at the onset of AD
[36]. In our study, co-cultures of iPSC-derived neurons
with primary astrocytes in MEAs showed an increase in
electrophysiological activity for TAU-mutant cells in com-
parison withWT. This result, in principle, appears contradic-
tory with the transcriptome data indicating the prevalence of
a GABAergic inhibitory phenotype within mutant cells.
Nevertheless, during development, there is developmental
shift in GABAergic populations from immature excitatory
to mature inhibitory synaptic transmission [38]. Immature
GABAergic neurons are not able to maintain a proper
reversal potential for the ion chloride (Cl2), resulting in a
higher intracellular Cl2 concentration compared with
mature neurons. This is because the chloride exporter
KCC2 (SLC12A5) is not yet expressed in immature GA-
BAergic neurons. After GABA synaptic transmission, this
deregulated Cl2 potential results into an outward Cl2 flux
and hence, an activating depolarization [39]. We therefore
queried the RNAseq data and found that the expression of
KCC2 (SLC12A5) was substantially decreased in mutant
neurons compared with WT cells mainly at later stages
(DIV110, Supplementary Fig. 5G), reconciling the observa-
tion of a higher electrophysiological activity with a predom-
inant GABAergic phenotype within TAU-mutant neurons.
Recently, it has been described that amyloid precursor pro-
tein deficiency leads to KCC2 degradation, causing impaired
chloride concentrations inside the neurons. This resulted in
deficient GABAergic inhibition in the hippocampus of pa-
tients with AD [40]. Our results might suggest a role for
aberrant TAU as well in this phenomenon.
The increased electrophysiological activity of TAU-
mutant cells in MEAs was not reproduced in whole cell
patch-clamps experiments. Possible explanations for this
might be as follows: (1) considerable fewer neurons are
sampled in patch-clamp studies compared with MEA anal-
ysis; (2) MEA experiments allow to determine neuronal
network signaling, in contrast to patch-clamp where only in-FLA 5.5.0 DTD  JALZ2627_proofdividual cell electrophysiological activities can be evalu-
ated; and (3) astrocytes are essential to support neuronal
activity both in vivo and in vitro and the absence of astrocytes
in the patch-clamp experiments might have had a negative
impact on the neuronal activity assessed [22].
Finally, we found defective cortical maturation in vitro
from triple TAU-mutant cells, with a notable impairment
in the capacity to differentiate toward SATB21 superficial
cortical layer neurons and a relative increase in cells with
deeper cortical layer markers. Concomitantly, we observed
a decreased frequency of TBR1-positive cells, a transcription
factor governing cortical layer formation with altered
expression in patients with AD [23]. Decreased cortical neu-
rogenesis have been described as well for haploinsufficient
progranulin mutant neuronal progeny derived from iPSCs
of frontotemporal dementia patients [41], which might sug-
gest that aberrant mechanisms convey in similar neurode-
generative consequences. The reason for the failure to
generate superficial layer cortical neurons observed in triple
TAU-mutant neurons is not clear, but one possibility is that
these cells might be more sensitive to (oxidative, ER/UPR,
and/or inflammatory) stress, as has been reported in patients
with AD [42], with therefore a more specific disappearance
of these cells from the culture. The loss of the predominantly
glutamatergic superficial layer neurons would result in an
imbalance of excitatory vs. inhibitory signaling [43], as we
have observed at the transcriptome level in our cultures.
In conclusion, we generated a hiPSC-derived TAU-
mutant model that reproduces key several neurodegenerative
phenotypes associated with tauopathies, such as altered TAU
expression, including phosphorylated isoforms, TAU aggre-
gation, defective neurite conformation, altered neuronal
maturation, enhanced electrophysiological excitability, and
upregulation of stress pathways. The robustness of the
footprint-free and nonadditional mutation-generated line,
together with the advantages inherent to iPSC-derived sys-
tems, makes the generated model an ideal candidate plat-
form for the identification of therapeutic targets
counteracting TAU pathology excluding the variability asso-
ciated with patient-derived cells.4. Experimental procedures
4.1. Human iPSC lines culture conditions, gene editing,
and selection
The hiPSC ChiPS6b healthy donor-derived WT cells
(purchased from Takara Bio Inc.) were maintained in
feeder-free conditions using E8medium (Life Technologies)
on QhESC-qualified matrigel (Becton Dickinson) and were
split twice a week using EDTA (Lonza).
4.2. Selection of TAU mutations
We aimed to generate a cell model that reproduces several
aspects of tauopathy-related neurodegeneration. Therefore,
we selected the N279K, P301L, and E10116 mutations 19 July 2018  8:16 pm  ce
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Fig. 6. qRT-PCR confirms increased stress pathway gene expression in TAU-mutant cortical progeny. (A–M) qRT-PCR analysis for genes implicated in oxida-
tive stress (A–D), ER/UPR stress (E–I), and inflammatory responses (WT: black and TAU-mutant iPSC: gray, J–M). Gene expression levels are shown as fold
changes relative to WT NPCs on DIV32 (gene expression was normalized to the housekeeping gene GAPDH). (N–P) Western blot experiments and
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1932present within the exon 10 or next intron of theMAPT gene.
These three mutations are the most prevalent in FTDP-17,
accounting for up to 60% of all cases [16]. Presence of the
N279K or P301L mutations causes early onset and aggres-
sive disease course, increased TAU-phosphorylated species
both in neurons and glia, and a higher prevalence of the path-
ogenic 4R TAU isoforms, altering the 3R/4R ratio [14]. The
E10116 mutation is located in the intron between exons 10
and 11, causing alterations in the stem-loop structure and
affecting splicing capacity of pre-mRNA, with increased
exon 10 incorporation as a result and, therefore, a higher
expression of the 4R TAU isoforms [15].7
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1962
1963
1964
1965
1966
19674.3. Design of gene-editing strategy
To accurately and efficiently target the exon 10 of the
MAPT gene, we developed a combination of specific target-
ing using CRISPR-FokI nucleases [17] together with the
construction of a template DNA vector harboring the three
selected mutations and a dual HYGR (positive)/TK (nega-
tive) selection cassette (backbone vector provided by Dr. Ko-
suke Yusa, Wellcome Trust Sanger Institute, UK [18]). This
template incorporated as well a 700 bp left and right homol-
ogy arms to allow homologous recombination of the DNA
template into the genome, which should result, in most
cases, in the incorporation of the three selected mutations.
To generate footprint-free mutant cell lines, we combined
this strategy with the use of the piggyBac transposase tech-
nology, which allows excision by recombining TTAA se-
quences contained in their integration sites (inverted
terminal repeats) [44]. Therefore, we introduced the selec-
tion cassette next to an endogenous TTAA sequence, such
that following cassette excision the TTAA remained,
without altering the genomic sequence, therefore generating
cell lines without any additional genetic alterations [18].
CRISPR-FokI nucleases were designed using the Zinc
Finger Consortium (ZiFiT) algorithm [45] covering the
target sequence. Target site 1: TTATTAATTATCTG-
CACCTT, target site 2: AGCAACGTCCAGTCCAAGTG.
The efficiency of the selected nucleases was tested and vali-
dated on HEK293T cells (not shown).1968
1969
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1972
1973
1974
19754.4. Nucleofection and selection
Nucleofection was performed as previously described
[46]. Briefly, two million hiPSCs were transfected with
5 mg donor vector, 3 mg of pSQT1601 plasmid encoding
for dCas9-FokI and 1 mg of each plasmid encoding forquantification of protein levels for the inflammatory response (tumor necrosis facto
DIV65. (Q) IPA analysis, based on RNA-seq analysis depicted in Fig. 5, of the NFk
expressed genes on TAU-mutant neurons). (R and S) Representative immunostaini
cells stained with antibodies against activated CASPASE3 and TUJ1. (T–U) Anal
DIV40 andDIV68 (a representative picture of TAU-mutant neurons at DIV40 is sho
were defined as those nuclei with smaller size and more concentrated Hoechst sign
dent differentiations. Hoechst 33258 (blue) was used as nuclear marker. Scale bar
periments. *P , .05, **P , .01.
FLA 5.5.0 DTD  JALZ2627_proofgRNAs directed toward left and right target sites using the
Amaxa Nucleofector, and the hESC Nucleofector Solution
Kit 2 (Amaxa, Lonza) using the program F16. Cells were
cultured in feeder-free conditions as previously described
in the presence of a ROCK inhibitor analog (Revitacell,
Life Technologies). Selection was initiated after 2–3 days
with 25–50 mg/mL of Hygromycin B (Sigma-Aldrich) and
maintained for 10–15 days. Recombinant colonies were
manually picked and expanded for further characterization.
Removal of the selection cassette from selected clones
was performed by nucleofection of 5 mg of the PiggyBac
Transposon. Two to 3 days after the transfection, cells
were treated with 0.5 mM 1-(2-deoxy-2-fluoro-beta-D-arabi-
nofuranosyl)-5-iodouracil (FIAU) for 7 days. GFP expres-
sion was monitored by immunofluorescence Qand FACS
during the selection process with both HYG and FIAU.
4.5. Flow cytometry
To determine the frequency of GFP1 cells during the
initial HYG and subsequent FIAU selection procedure, cells
were enzymatically harvested using accutase, centrifuged,
and resuspended in 100 mL FACS buffer (PBS 1!, 2% fetal
bovine serum and 0.02% sodium azide). Cells were analyzed
on a FACSCanto flow cytometer using the FACS DIVA soft-
ware (Becton &Dickinson). After exclusion of cell doublets,
GFP fluorescence was determined on FL1-FITC channel,
with gates established based on fluorescence of untargeted
(WT) cells.
All results were analyzed using Flow Jo (FlowJo, LLC,
USA) and FACS DIVA software (Becton & Dickinson).
Flow cytometry and FACS sorting was performed at the
KU Leuven Flow Cytometry Facility.
4.6. PCR genotyping
PCR genotyping was done using 40 ng of genomic DNA
with Go Taq DNA polymerase (Promega) in 10 mL reactions.
Primer sequences and PCR program conditions are
described in Supplementary Table 1. PCR products were
loaded on 1.5% agarose (Sigma) gels and visualized with
SYBR Safe (Invitrogen) on a Gel Doc XR1 System (Bio-
Rad).
4.7. Pluripotency characterization
Both WT and triple TAU-mutant cells were subjected to
spontaneous differentiation mediated by embryoid body for-
mation and subsequently analyzed for the three-lineager receptor 1 (TNFR1)) and ER/UPR stress (CHOP) markers respectively, on
B signaling pathway (red: highly expressed genes onWT cells; green: highly
ng images and quantification on DIV40 and DIV68 of WTand TAU-mutant
ysis of apoptotic nuclei in WT and TAU-mutant cortical neuron progeny on
wn for immunostainingwith TUJI antibodies andHoechst). Apoptotic nuclei
al, lacking expression of TUJI. Representative images of N5 3–4 indepen-
: 50 mm. Data are represented as mean 6 SEM of N 5 3–4 independent ex-
 19 July 2018  8:16 pm  ce
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20954.8. Neuronal differentiation protocol
Cortical neurons were generated from both WTand triple
TAU mutant hiPSCs as previously described by Shi et al.
[19]. Briefly, single-cell hiPSCs were collected and plated
on Matrigel-coated (BD) well plates in E8 medium supple-
mented with ROCK inhibitor analog (Revitacell, Life Tech-
nologies). Once the cell culture reached 95% confluence,
neural induction was initiated by changing the culture me-
dium to N2B27 medium, consisting of a 1:1 mixture of
N2- and B27-containing media. N2 medium consisted of
DMEM/F12, N2, 5 mg/mL insulin, 1! GlutaMax, 1!
nonessential amino acids, 1! 2-mercaptoethanol, 1! peni-
cillin/streptomycin. B27 medium consisted of Neurobasal,
B27 without retinoic acid, 1! glutamax, 1 ! 200 mM
glutamine and 1! penicillin/streptomycin (all from Life
Technologies). N2B27 medium was supplemented with
the small molecules SB431542 10 mM (Tocris) and
LDN193189 1 mM (Miltenyi Biotec), and daily medium
changes were performed till day 12. Then, neuroepithelial
cells were collected by dissociation with dispase and
replated in N2B27 medium, including 20 ng/mL bFGF (Pe-
protech) on matrigel-coated dishes. Rosette-forming neuro-
epithelial cells were purified two more times (one each after
4–5 days), after which single-cell splitting with accutase was
performed twice before cryopreserving NPCs (which
occurred on DIV32–33). For terminal neuronal differentia-
tion, NPCs were thawed, cultured in N2B27 medium for a
few days, and replated on DIV40-42 at 15–25.000 cells
per cm2 on poly-ornithine and laminin-coated plastic dishes
in N2B27 medium and maintained for up to DIV200 with
partial medium changes twice a week.2096
2097
2098
2099
2100
2101
2102
2103
2104
2105
2106
2107
2108
2109
2110
2111
2112
2113
2114
2115
2116
2117
2118
21194.9. RNA extraction, cDNA synthesis, and gene expression
(QPCR)
Total RNA was purified using the GenElute Mamma-
lian Total RNA Miniprep Kit (Sigma-Aldrich, Saint Louis,
MO, USA) and ZR RNA MicroPrep (Zymo Research, CA,
USA). After concentration and integrity validation (Nano-
Drop 1000, Thermo Fisher Scientific, MA USA), cDNA
was generated using 0.5–1 mg of RNA with SuperScript
III First-Strand Synthesis SuperMix for qRT-PCR kit (Invi-
trogen, CA, USA), and qRT-PCRwas performed in technical
triplicates on a ViiA 7 Real-Time PCR System with 384-
well plate (Applied Biosystems, Carlsbad, CA, USA) with a
Platinum SYBR Green qPCR SuperMix-UDG w/ROX
(Invitrogen, CA, USA) and primers mix at final concentra-
tion of 250 nM.
Gene expression (cycle threshold) values were normal-
ized based on the GAPDH (glyceraldehyde 3-phosphate de-
hydrogenase) housekeeping gene, and the delta CTFLA 5.5.0 DTD  JALZ2627_proofcalculated. Gene-specific primers were designed in exon-
exon spanning regions in common domains of all isoforms
described for a given gene. The efficiency of primers was
tested by serial dilutions of cDNA and by calculating the co-
efficient of regression (R2). An efficiency of 90%–105%
with an R2  95% was accepted. See Supplementary
Table 2 for a list of all qRT-PCR primers used in this study.
Identification of the 3R or 4R species was done using
the following TaqMan assays (Thermofisher): glyceralde-
hyde 3-phosphate dehydrogenase (Hs99999905_m1),
MAPT all isoforms (Hs00902194_m1), MAPT 3R iso-
forms (Hs00902192_m1), and MAPT 4R isoforms
(Hs00902312_m1).4.10. Transcriptome analysis by RNA sequencing
Total RNA was purified using the GenElute Mamma-
lian Total RNA Miniprep Kit (Sigma). RNA concentration
and purity were determined spectrophotometrically using
the NanoDrop ND-1000 (NanoDrop Technologies), and
RNA integrity was assessed using a Bioanalyzer 2100 (Agi-
lent). Per sample, an amount of 100 ng of total RNA was
used as input. Using the Illumina TruSeq Stranded
mRNA Sample Prep Kit (protocol 15031047 Rev.E
“October 2013”), poly-A–containing mRNA molecules
were purified from the total RNA input using poly-T oligo-
attached magnetic beads. In a reverse transcription reaction
using random primers, RNA was converted into first strand
cDNA and subsequently converted into double-stranded
cDNA in a second strand cDNA synthesis reaction using
DNA Polymerase I and RNAse H. The cDNA fragments
were extended with a single deoxyadenosine to the 30 ends
of the blunt-ended cDNA fragments after which multiple in-
dexing adapters were ligated, introducing different barcodes
for each sample. Finally, enrichment PCR was carried out to
enrich DNA fragments that had adapter molecules on both
ends and to amplify the DNA in the library. Sequence li-
braries of each sample were equimolar pooled and
sequenced on an Illumina NextSeq 500 instrument (High
Output, 75 bp, Single Reads, v2) at the VIB Nucleomics
core (www.nucleomics.be).
Low-quality ends and adapter sequences were trimmed
off from the Illumina reads. Subsequently, small reads
(length , 35 bp), ambiguous reads (containing N), and
low-quality reads (more than 50% of the bases , Q25)
were filtered. Processed reads were aligned with Tophat,
v2.0.8b, to the human reference genome (GRCh38), as
downloaded from the Genome Reference Consortium
(https://www.ncbi.nlm.nih.gov/grc/human/data). Default
Tophat parameter settings were used, except for “min-
intron-length 5 50”, “max-intron-length 5 500,000”, “no
coverage-search” and “read-realign-edit-dist 5 3”.
Principal component analysis and volcano plots were
generated in the statistical software R, version 3.4.1. Clus-
tering was performed with ClustVis [48]. Differentially ex-
pressed genes were identified based on P . .05, and a fold 19 July 2018  8:16 pm  ce
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2220change of two or more in gene expression among the
different pair-wise comparison was used to identify the
differentially expressed genes. Gene ontology of
the different differentially expressed genes was carried out
using the Gene Ontology Consortium (http://www.
geneontology.org/). Ingenuity pathway analysis was per-
formed with build 456367, content version 39480507.
4.11. Western blot
Cells were lysed and sonicated in RIPA buffer (Sigma),
containing phosphatase and protease inhibitors. Lysate was
cleared by 15 min centrifugation at 12,000! g, and superna-
tant was recovered for protein quantification. Twenty micro-
grams of protein extract was then loaded per lane and
resolved on SDS-PAGE before transferring to nitrocellulose
membranes. Blocking was done for 1 h with 5% nonfat milk
solution in PBST before incubation with primary antibodies.
For TAU WBs, cells were lysed in RIPA buffer (150 mM
NaCl, 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM
EDTA, 1% NP-40, 0.25% sodium deoxycholate supple-
mented with complete protease inhibitors (Roche) and Phos-
STOP (Sigma). The homogenate was ultra-centrifuged at
100,000! g for 60 min at 4C. Equal amounts of protein
were taken and analyzed by SDS–PAGE and semi-
quantitativeWestern immunoblot. Bands were visualized us-
ing a cooled charge-coupled device camera (ImageQuant
LAS-4000; GE Healthcare) and quantified by AIDA Image
Analyzer software.11 2221
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22535. AlphaLISA immunoassay
Cell lysis was performed using RIPA buffer containing
phosphatase (PhosSTOP, Roche, Mannheim, Germany)
and protease inhibitors (cOmplete, Roche) in culture plates
for 1 h at room temperature (RT) on an orbital shaker. For
hTAU10/hTAU10 TAU aggregation assays, we performed
measurements in duplicates using 5 mL of lysate each
time. Five microliters of the remaining lysate were used
for the relative quantification of total TAU and for measuring
cell viability, respectively. Each sample was transferred to a
384-well assay plate for AlphaLISA reaction, in which 5 mL
of cell extracts were incubated for 2 h at RTwith a mixture of
biotinylated antibody and acceptor beads. Subsequently,
donor beads were added to the wells and incubated at RT
for 30 min before reading at 615 nm (on illumination at
680 nm) on the EnVision plate reader (PerkinElmer, Wal-
tham, MA). Output measurement is quantified as relative
fluorescent units and compared versus control conditions.
5.1. Immunostainings
Cells were washed with PBS 1! and fixed for 15 min at
RT with 4% formaldehyde solution and washed with PBS.
Preparations were permeabilized in 0.1% Triton-X-100
(Sigma) and blocked in 10% donkey or goat serum (Dako)
in PBS for 1 h at RT. Primary antibodies were incubatedFLA 5.5.0 DTD  JALZ2627_proofovernight at 4C in 5% in donkey or goat serum in PBS,
washed 3 times, and incubated for 1 h at RT with fluores-
cently labeled secondary antibodies diluted to 1:500. Sam-
ples were incubated for 15 min at RT with Hoechst 33258
(1:2000 dilution) for nuclear staining and mounted with
ProLong Gold Antifade Mountant (Thermo Fisher Scienti-
fic). The list of primary and secondary antibodies and the di-
lutions used can be found in Supplementary Tables 3 and 4.
5.2. Image acquisition and analysis
The stained cells were examined using an Axioimager.Z1
microscope (Carl Zeiss). For quantification purposes, at least
five independent fields per condition and per experiment
were obtained. For neurite outgrowth experiments, images
were acquired on an In Cell Analyzer 2000 High Content
Imager (GEHealthcare), acquiring sufficient numbers of im-
ages to cover at least 70% of the well area. Data analysis was
performed using the In Cell image analysis software (GE
Healthcare), with the specific software package of neurite
outgrowth.
5.3. EdU incorporation assays
Cells were pulse-labeled with 10 mM 5-ethynyl-20-deox-
yuridine (EdU, Life Technologies) for 3 hours, and several
medium washes were performed afterward. Twenty-four
hours after onset of EdU incubation, cells were fixed with
4% PFA for 15 minutes, washed with PBS 1 2% BSA, fol-
lowed Qby 300 permeabilization with PBS 1 0.5% Triton.
Cells were then incubated for 30 min at RTwith freshly pre-
pared reaction buffer (per mL: 976 mL PBS 1 10 mL
CuSO4 1 10 mL Sodium Ascorbic 1 4 mL of 1/100
Azide-AF647 antibody), washed for three times, and stained
with b-3-tubulin and Hoechst. The presence of EdU1 cells
was evaluated using an Axioimager.Z1 microscope (Carl
Zeiss).
5.4. Electrophysiological recordings
Whole-cell patch-clamp recordings of hIPSC-derived
cortical neurons were carried out in a recording chamber
which was continuously perfused with artificial cerebrospi-
nal fluid at RT. Artificial cerebrospinal fluid contained
145 mM NaCl, 5 mM KCl, 2 mM CaCl2, 2 mM MgCl2,
10 mM Hepes, and 12 mM glucose (pH adjusted to 7.4
with NaOH;w310 mOsm). Cells were visualized by an in-
verted Olympus IX73 microscope equipped with a 40!
objective. Recording patch pipettes were pulled from boro-
silicate glass using a vertical PIP6 micropipette puller
(HEKA Elektronik, Lambrecht/Pfalz, Germany) and filled
with an internal solution containing (in mM): 120 K-gluco-
nate, 20 KCl, 1 MgCl2, 10 Hepes, 0.2 EGTA, 0.3 Na-GTP, 5
NaCl, 4 Mg-ATP (pH adjusted to 7.3 with KOH; w290
mOsm). Current-clamp mode was applied to measure action
potentials, while voltage-gated Na1 and K1 currents were
recorded in voltage-clamp mode. An online P4 leak 19 July 2018  8:16 pm  ce
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2331subtraction protocol was applied during the acquisition of all
voltage-gated currents. Details of the performed current- and
voltage-clamp protocols are described in the results section.
Signals were acquired, filtered (at 2.8 kHz), and digitized (at
20 kHz) using an EPC10 USB amplifier and PatchMaster
software (HEKA Elektronik). The liquid junction potential
of 14 mV was corrected off-line. Action potential detection
was performed using Stimfit software; current amplitudes
were measured by PatchMaster software.2332
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23645.5. Multi-electrode arrays
Human iPSC-derived NPCs (DIV30) were co-cultured
with rat primary astrocytes in 1:1 ratio and plated onto 48-
well MEA plates (Axion BioSystems) coated with polyethy-
leneimine and laminin. Plating was done using drop seeding
method, where 15 mL of mixed cells (60,000 cells in total) in
a 10% dilution of N2B27media: Matrigel (BD Biosciences,
Cat#356230) was placed onto each well. Cells were then
cultured in neuronal differentiation media for up to 40 addi-
tional days (DIV70), with partial medium replacements
every 2–3 days. Spontaneous network activity of the matu-
rating neurons was recorded for 5 minutes on specific time
points using the Axion Biosystems Maestro MEA at 37C
and 5% CO2.
Data analysis was performed using AxIs software (Axion
Biosystems) to obtain from the recording the data concern-
ing the spikes, bursts, and network activity. Quality criteria
for the assays were defined as follows: active electrodes
were defined as an electrode having an average of more
than five spikes per minute. Wells in which less than 30%
of electrodes were active were considered inactive and
removed from analysis. For synchronous network activity,
at least 25% of the total electrode in a well was required to
participate in a network event in order for the network to
be qualified as network spike or bursts.15
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23805.6. Statistical analysis
Comparisons between two groups were analyzed using
unpaired or paired two-tailed Student’s t test. P-values
, .05 were considered significant (*). Data are shown as
mean, and error bars represent standard error of mean of a
minimum three independent experiments.
For patch-clamp data, a Mann-Whitney test or a Kruskal-
Wallis with post hoc Dunn’s multiple comparison’s test were
used to compare respectively two or three groups as patch
clamp data were not normally distributed. Results were
plotted and analyzed using GraphPad Prism 6 software.2381
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